

**BIOCON GROUP**

**FACT SHEET**

**December - 2013**

**YTD FY 2014 vs. YTD FY 2013**

**Q3 FY 2014 vs. Q3 FY 2013**

<b>BIOCON LIMITED (CONSOLIDATED) UNAUDITED BALANCE SHEET</b>		<b>(Rs. Crores)</b>
	<b>December 31, 2013</b>	<b>March 31, 2013</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholder's Funds</b>		
(a) Share capital	100	100
(b) Reserves and surplus	2,936	2,595
	<b>3,036</b>	<b>2,695</b>
<b>Minority interest</b>	76	65
<b>Non-current liabilities</b>		
(a) Long-term borrowings	475	164
(b) Deferred tax liability (net)	35	41
(c) Other long-term liabilities	550	424
(d) Long-term provisions	7	4
	<b>1,067</b>	<b>633</b>
<b>Current liabilities</b>		
(a) Short-term borrowings	62	85
(b) Trade payables	390	345
(c) Other current liabilities	359	347
(d) Short-term provisions	102	246
	<b>913</b>	<b>1,023</b>
<b>TOTAL</b>	<b>5,092</b>	<b>4,416</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Fixed assets	2,337	1,811
(b) Goodwill	12	12
(c) Non-current investments	65	64
(d) Long term loans and advances	274	248
(e) Other non-current assets	52	41
	<b>2,740</b>	<b>2,176</b>
<b>Current assets</b>		
(a) Current Investments	388	522
(b) Inventories	443	398
(c) Trade receivables	621	510
(d) Cash and cash equivalents	661	673
(e) Short term loans and advances	159	81
(f) Other current assets	80	56
	<b>2,352</b>	<b>2,240</b>
<b>TOTAL</b>	<b>5,092</b>	<b>4,416</b>

<b>BIOCON LIMITED (CONSOLIDATED) UNAUDITED</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
Particulars	9M FY 14	9M FY 13	Variance
<b>INCOME</b>			
<b>Biopharmaceuticals</b>	<b>1,603</b>	<b>1,406</b>	<b>14%</b>
Biopharma *	1,304	1,143	14%
Branded formulations - India	299	263	14%
<b>Contract research</b>	<b>526</b>	<b>391</b>	<b>35%</b>
<b>Total Sales</b>	<b>2,129</b>	<b>1,797</b>	<b>18%</b>
Other income	58	92	-37%
<b>Total Revenue</b>	<b>2,187</b>	<b>1,889</b>	<b>16%</b>
<b>EXPENDITURE</b>			
Material & Power costs	1,016	877	16%
Staff costs	317	259	22%
Research & Development **	102	121	-16%
Other expenses	202	160	26%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,637</b>	<b>1,417</b>	<b>16%</b>
<b>EBITDA</b>	<b>550</b>	<b>472</b>	<b>17%</b>
Interest & Finance charges	1	7	
Depreciation & Amortisation	149	134	11%
<b>PBT</b>	<b>400</b>	<b>331</b>	<b>21%</b>
Taxes	88	69	28%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>312</b>	<b>262</b>	<b>19%</b>
Minority interest	11	2	
<b>NET PROFIT FOR THE PERIOD</b>	<b>301</b>	<b>260</b>	<b>16%</b>
<b>EPS Rs.</b>	<b>15.0</b>	<b>13.3</b>	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharmaceuticals Income includes:			
Licensing Income	15	23	
** Gross Research & Development expenses	114	149	

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED**  
**PROFIT & LOSS STATEMENT** **(Rs. Crores)**

Particulars	Q3 FY 14	Q3 FY 13	Variance
<b>INCOME</b>			
<b>Biopharmaceuticals</b>	<b>517</b>	<b>495</b>	<b>4%</b>
Biopharma *	418	409	2%
Branded formulations - India	99	86	15%
<b>Contract research</b>	<b>183</b>	<b>140</b>	<b>31%</b>
<b>Total Sales</b>	<b>700</b>	<b>635</b>	<b>10%</b>
Other income	19	25	-24%
<b>TOTAL REVENUE</b>	<b>719</b>	<b>660</b>	<b>9%</b>
<b>EXPENDITURE</b>			
Material & Power costs	338	307	10%
Staff costs	107	88	22%
Research & Development **	20	43	-53%
Other expenses	67	55	22%
<b>Manufacturing, staff &amp; other expenses</b>	<b>532</b>	<b>493</b>	<b>8%</b>
<b>EBITDA</b>	<b>187</b>	<b>167</b>	<b>12%</b>
Interest & Finance charges	-	3	
Depreciation & Amortisation	51	46	11%
<b>PBT</b>	<b>136</b>	<b>118</b>	<b>15%</b>
Taxes	26	25	4%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>110</b>	<b>93</b>	<b>18%</b>
Minority interest	5	1	
<b>NET PROFIT FOR THE PERIOD</b>	<b>105</b>	<b>92</b>	<b>14%</b>
<b>EPS Rs.</b>	<b>5.2</b>	<b>4.7</b>	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	4	9	
** Gross Research & Development expenses	23	49	